Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
Symptomatic NOH in patients with primary autonomic failure is thought to be a consequence of
norepinephrine depletion leading to a diminished capacity to effect an appropriate
cardiovascular response to an orthostatic challenge resulting in symptomatic
cerebral-hypoperfusion. Droxidopa augments norepinephrine levels which should lead to
improved cerebral perfusion following orthostatic challenge thereby reducing the symptoms of
NOH. The present study will evaluate the long-term safety of droxidopa.